##  [What Is Regulatory Approval for Human and Veterinary medicines in South Africa? A Technical Deep Dive Into Frameworks, Challenges & Emerging Trends](/index%2Ephp/what-is-regulatory-approval-for-human-and-veterinary-medicines-in-south-africa-a-technical-deep-dive-into-frameworks-challenges-emerging-trends) 

2 min read 

 Your browser does not support the audio element.





## 1. What Is Regulatory Approval?

Regulatory approval in South Africa refers to the **scientific and administrative process** administered by the South African Health Products Regulatory Authority (SAHPRA), under the Medicines and Related Substances Act 101 of 1965. It ensures that human/veterinary medicinal products entering the market satisfy the three core pillars of **quality, safety, and efficacy**.

- Applicants must compile a dossier in CTD/eCTD format (Modules 1–5), adhering to SAHPRA’s regional specifications.
- Registration creates legal authority for marketing, distribution, and post-market activities (labeling, pharmacovigilance, batch-release) in South Africa.

## 2. What Is the Regulatory Framework for Medicine Approvals?

**2.1 Submission Formats & Technical Dossier**

The SAHPRA guideline *“Guidance for the Submission of the South African CTD-eCTD – General & Module”* (Doc 2.24 v6) outlines the structure and expectations of the dossier.

- Module 1 (administrative/local information) is region-specific and essential for SAHPRA review.
- SAHPRA now mandates the use of the eCTD portal for submissions.
- The *Reliance Guideline* (SAHPGL-BAU-01, 2025) sets out abridged and recognition pathways leveraging trusted reference regulators.

**2.2 Review Pathways**

- **Full Review**: Traditional path for new chemical entities (NCEs), novel biologics, and first-in-country submissions.
- **Abridged/Recognition/Reliance**: SAHPRA may rely on prior approval by recognised regulators (US FDA, EMA, TGA, Health Canada) to reduce review burden.
- **Conditional/Section 21 Access**: For unregistered medicines under exceptional circumstances, public-health emergencies, or named-patient access.

**2.3 Post-Approval and Lifecycle Management**

- SAHPRA’s *Risk Management Plan (RMP) Guideline* (SAHPGL-CEM-PV-03) sets expectations for pharmacovigilance, safety updates, and periodic review.
- Variations and renewals are governed by SAHPRA guidelines (SAHPGL-HPA-06) and the general information guideline.

## 3. What Are the Current Challenges?

- **Review backlog & inconsistent timelines**: Despite efforts to clear backlogs, full-review pathway timelines may stretch up to 48 months for complex dossiers.
- **Submission quality**: Poorly formatted or incomplete dossiers often lead to review delays, emphasising the importance of consistent CTD structure and regional Module 1 compliance.
- **Harmonisation vs local adaptation**: Although SAHPRA aligns with ICH standards, local requirements (labeling, language, public-health priorities) remain. Applicants must navigate both global and national norms.
- **Inspection and GMP capacity**: Manufacturing-site inspections, especially for imported products, are still a bottleneck in many cases.
- **Emerging product types**: Advanced therapies (gene, cell, tissue), AI/ML-enabled devices, and biosimilars pose Regulatory complexity in a framework still adapting.

## 4. What Are the Emerging Trends?

- **Digitisation & eCTD adoption**: SAHPRA’s eCTD portal supports validation criteria, full traceability, and lifecycle management (sequence submissions).
- **Regulatory reliance and regional collaboration**: Use of reliance pathways and participation in initiatives such as the ZaZiBoNa Collaborative Medicines Registration Programme and the African Medicines Agency (AMA) are increasing efficiency across Africa.
- **Stronger vigilance & RMP expectations**: SAHPRA emphasises proactive risk-management and integrated safety surveillance post-registration.
- **Expansion of advanced-therapy regulation**: With biologics, biosimilars, and cell/gene therapies growing, SAHPRA is adapting guidelines and leveraging international reference frameworks.

## 5. What Should Sponsors Focus On Technically?

- **Dossier-format integrity**: Ensure CTD Modules 1–5 is complete, logically structured, with robust Module 2 summaries drawing from Modules 3–5. Use SAHPRA’s eCTD validation criteria.
- **Data bridging & reliance justification**: If leveraging a reliance pathway, you must clearly map foreign authority approvals, justify differences, and demonstrate comparability.
- **Local agent/MAH governance**: The authorised person/local MAH must be registered in South Africa and listed in the dossier (Module 1).
- **Manufacturing site readiness**: GMP certificate, site master files, validation data, and inspection history must satisfy SAHPRA’s GMP guideline (SAHPGL-INSP-02) and inspection readiness expectations.
- **Lifecycle infrastructure**: Ensure you have a pharmacovigilance system master file (PSMF), RMP, variation strategy, and renewal calendar to manage the full product lifecycle.

Ready to navigate SAHPRA’s advanced Regulatory landscape with certainty and technical precision?[**Contact our Regulatory experts today**](https://www.freyrsolutions.com/medicinal-products/pharma-regulatory-services-in-south-africa) to build a tailored strategy, optimise your CTD/eCTD dossier, and secure compliant, efficient market access in South Africa.